Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity MarketThe Motley Fool • 10/09/25
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitisPRNewsWire • 10/07/25
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be AppreciatedSeeking Alpha • 10/03/25
These high-quality stocks are helping this large-cap Janus mutual fund beat its peersMarket Watch • 10/02/25
3 Blue Chip Stocks That Have Soared 380% (and Higher) Over the Past 5 YearsThe Motley Fool • 10/02/25
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors sayReuters • 10/02/25